Thyme Care Stock
| Valuation | $2B1 |
| Valuation Date | Sep 2, 2026 |
| Implied Valuation | $2B |
| Last Price | $5.00 |
| 52-Week High | $6.00 |
| 52-Week Low | $5.00 |
| YTD Return | n/a |
| 1-Year Return | n/a |
| 3-Year Return | n/a |
| Total Funding | $360M2, 3 |
| Latest Round Amount | $125M3 |
| Latest Round | Series E |
| Funding Rounds | 5 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Thyme Care
Thyme Care is a value-based oncology company that guides people through cancer treatment with a technology-enabled, human-powered care model. It partners with health plans, employers and risk-bearing providers to take on accountability for oncology populations, pairing an oncology-trained team of nurses, social workers and physicians with data and technology that supports patients from diagnosis through active treatment. The company makes money through value-based, at-risk contracts with payers and providers, aligning its payment to lower total cost of care and better outcomes rather than fee-for-service billing. Thyme Care now operates as the anchor business of parent company Thyme Companies.
Invest in Thyme Care
Thyme Care is a private company, so you can't purchase it with a regular brokerage account. However, its shares are available on Clarity (formerly Hiive).
Clarity is a secondary marketplace where accredited investors can buy and sell shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on ClarityStock Analysis may be compensated for user sign-ups through Clarity links. Clarity is not affiliated with Stock Analysis. Securities offered by Clarity Capital Limited, member of FINRA/SIPC.
News
Thyme Companies Names Carolyn Starrett as Executive Vice President, New Ventures
Thyme Companies hired former Flatiron Health CEO Carolyn Starrett as EVP of new ventures on September 29, 2026 to accelerate oncology businesses beyond the core Thyme Care platform.
Oncology company Thyme Care raises $125M, backed by Morgan Health, Humana and CVS Health Ventures
Fierce Healthcare covered Thyme Care's Series E as the company expands beyond cancer navigation under its new Thyme Companies parent.
Thyme Care Closes $125+ Million Series E, Establishes Thyme Companies
Thyme Care raised over $125 million in Series E funding led by Morgan Health at a valuation above $2 billion and formed parent entity Thyme Companies.
Thyme Care raises $125 million, cancer startup's value over $2 billion
Thyme Care closed a Series E of more than $125 million led by Morgan Health, roughly doubling its valuation to above $2 billion. The company also launched a new parent organization, Thyme Companies, t...
Thyme Care Evolves Leadership: Dr. Brad Diephuis Named CEO
Brad Diephuis became Thyme Care CEO effective Sept. 1, 2026, while co-founder Robin Shah moved to executive chairman of parent Thyme Companies.
Founder Of $1 Billion Cancer Care Startup Steps Down As CEO
Co-founder Robin Shah announced he would step down as CEO effective September 1, moving to executive chairman. Dr. Brad Diephuis, previously president and chief operating officer, was named to succeed...
Blue Cross Blue Shield of Massachusetts Expands Cancer Care Support for Members With Thyme Care
Blue Cross Blue Shield of Massachusetts signed its first oncology-focused outcomes-based contract with Thyme Care in June 2026, giving eligible members access to dedicated cancer navigation support.
Blue Cross Blue Shield of Massachusetts Expands Cancer Care Support for Members with Thyme Care
Blue Cross Blue Shield of Massachusetts announced its first oncology-focused, outcomes-based contract with Thyme Care. Eligible members with a suspected or confirmed cancer diagnosis gain access to a ...
Thyme Care named No. 18 on the 2026 CNBC Disruptor 50 list
Thyme Care was ranked No. 18 on CNBC's 2026 Disruptor 50 list of innovative private companies. The company said it drives greater than 5% medical expense reduction for many health plan partners.
CenterWell Partners with Thyme Care for Comprehensive Cancer Care Support
LOUISVILLE, Ky.--(BUSINESS WIRE)--CenterWell partners with Thyme Care for comprehensive cancer care support.
Thyme Care lands $97M Series D backed by CVS Health, Humana, Morgan Health and Memorial Hermann
Thyme Care raised $97 million in Series D funding, pushing its valuation above $1 billion. New strategic investors included Morgan Health, Humana, Texas Oncology and Memorial Hermann Health System.
Humana Expands Value-Based Oncology Care Through New Agreement with Thyme Care
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana expands value-based oncology care for eligible Medicare Advantage members through new agreement with Thyme Care.
Thyme Care Closes $95M Series C To Fuel Cancer Care Affordability
Thyme Care closed a $95 million capital raise, including $55 million in equity led by new investor Concord Health Partners and $40 million in debt from Banc of California. The round brought total capi...
Thyme Care Secures $60M Series B to Scale Cancer Care Beyond the Clinic
Thyme Care raised a $60 million Series B co-led by Town Hall Ventures and Foresite Capital. The company said it would use the capital to expand its national network of oncology partners into new marke...
Andreessen Horowitz Leads $22M in Funding for Thyme Care
Thyme Care closed $22 million in funding led by Andreessen Horowitz, AlleyCorp and Frist Cressey Ventures, with participation from Casdin Capital and Bessemer. The company said it would use the capita...
Thyme Care Announces Strategic Partnership with Clover Health to Support Members Navigating Through Their Cancer Journey
NASHVILLE, Tenn.--(BUSINESS WIRE)-- #cancer--Thyme Care announces strategic partnership with Clover Health to support members navigating through their cancer journey